.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
AstraZeneca
US Army
Novartis
Merck
Teva
McKinsey
Cipla
Deloitte
Queensland Health

Generated: June 25, 2017

DrugPatentWatch Database Preview

Fluocinolone acetonide; hydroquinone; tretinoin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for fluocinolone acetonide; hydroquinone; tretinoin and what is the scope of fluocinolone acetonide; hydroquinone; tretinoin freedom to operate?

Fluocinolone acetonide; hydroquinone; tretinoin
is the generic ingredient in one branded drug marketed by Galderma Labs Lp and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fluocinolone acetonide; hydroquinone; tretinoin has twenty-four patent family members in eighteen countries.

There are twelve drug master file entries for fluocinolone acetonide; hydroquinone; tretinoin. One supplier is listed for this compound.

Summary for Generic Name: fluocinolone acetonide; hydroquinone; tretinoin

Tradenames:1
Patents:4
Applicants:1
NDAs:1
Drug Master File Entries: see list12
Suppliers / Packagers: see list1
Clinical Trials: see list238
Drug Prices:see low prices
DailyMed Link:fluocinolone acetonide; hydroquinone; tretinoin at DailyMed

Pharmacology for Ingredient: fluocinolone acetonide; hydroquinone; tretinoin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galderma Labs Lp
TRI-LUMA
fluocinolone acetonide; hydroquinone; tretinoin
CREAM;TOPICAL021112-001Jan 18, 2002RXYesYes7,939,516► SubscribeY ► Subscribe
Galderma Labs Lp
TRI-LUMA
fluocinolone acetonide; hydroquinone; tretinoin
CREAM;TOPICAL021112-001Jan 18, 2002RXYesYes8,653,053► SubscribeY ► Subscribe
Galderma Labs Lp
TRI-LUMA
fluocinolone acetonide; hydroquinone; tretinoin
CREAM;TOPICAL021112-001Jan 18, 2002RXYesYes8,247,395► SubscribeY ► Subscribe
Galderma Labs Lp
TRI-LUMA
fluocinolone acetonide; hydroquinone; tretinoin
CREAM;TOPICAL021112-001Jan 18, 2002RXYesYes7,915,243► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: fluocinolone acetonide; hydroquinone; tretinoin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,544,674Topical skin care composition► Subscribe
9,333,172Topical skin care composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fluocinolone acetonide; hydroquinone; tretinoin

Country Document Number Estimated Expiration
Hong Kong1088831► Subscribe
Japan2006507285► Subscribe
South Korea100852367► Subscribe
MexicoPA05004404► Subscribe
European Patent Office1562531► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Julphar
Deloitte
Cantor Fitzgerald
Mallinckrodt
Teva
McKesson
Cipla
Cerilliant
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot